Sanofi SA vs Vanguard Total World Stock Index Fund ETF — how do they compare? Sanofi SA trades at $40.17 (market cap $95.18B), while Vanguard Total World Stock Index Fund ETF trades at $159.62 (market cap $101.70B). The key difference: Sanofi SA and Vanguard Total World Stock Index Fund ETF are close in size by market cap, and Sanofi SA pays a 6.01% dividend while Vanguard Total World Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Vanguard Total World Stock Index Fund ETF for 53 Days on average.
| SNY | VT | |
|---|---|---|
Market Cap | $95.18B | $101.70B |
Volume | 2,995,646 | 1,783,794 |
Sector | Health | Broad Market / Factor |
52-Week High | $52.34 | $162.39 |
52-Week Low | $39.51 | $134.19 |
Typical Hold Time | 94 Days | 53 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
VT, the Vanguard Total World Stock ETF, trades at $159.39, down 0.16% on the day. Technical indicators show a bearish bias with moving averages signaling selling pressure, while oscillators remain neutral. The ETF offers broad global diversification with over 9,700 stocks and a low expense ratio of 0.06%, though key valuation ratios like P/E and P/B are not disclosed in the provided data. Recent news highlights its role as a core holding for long-term investors seeking worldwide exposure.
The outlook for VT is supported by its cost efficiency and diversification benefits, but near-term technical weakness and competitive pressures from lower-fee alternatives pose risks. Investor sentiment is mixed, with some analysts favoring VT for its comprehensive coverage, while others point to higher expenses relative to peers. Macroeconomic uncertainties and trade tensions could impact global equity returns, affecting VT's performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →